A recent Technology Transfer Tactics article by Jesse
Schwartz published on February 22, 2017 states that universities are bringing
more intellectual property suits, particularly patent infringement actions,
against large companies. Notably, the
article points to the University of Minnesota infringement suit against Gilead
Life Sciences and states:
Litigation like the UM lawsuit indicates that universities
are warming up to the idea that fighting for their patent rights is worth the
effort and expense, says Joshua H. Haffner, JD, an attorney with Haffner Law in
Los Angeles. The UM case continues a trend of schools stepping up and demanding
payment for use of their patents, he notes. Carnegie Mellon University settled
a patent infringement case with Marvell Technology Group for $750 million in
2016, and later that year a jury ordered Apple to pay the University of
Wisconsin more than $234 million for using its microchip technology in iPhones
and iPads without permission. In 2015, a jury awarded Boston University more
than $13 million from three companies that infringed on its patent for blue
light emitting diodes (LEDs).
“This trend is continuing because they’re making money off
the cases,” Haffner says. “Patent infringement cases can be very profitable,
and with every win by a university others are looking at that and saying maybe
they could reap the same rewards. There are other principles at play, like
protecting the inventors and the principle of ownership, but really if the
invention is not making money those principles tend to fall by the wayside.”
Interestingly, the Patent Trial
and Appeal Board (PTAB) recently decided the Covidien v. University of Florida
Research Foundation (UFRF) matter. In
that matter, the PTAB analogized inter partes review proceedings (IPRs) to
litigation and decided that public (state) universities have 11th
Amendment immunity against IPRs.
Basically, this means that parties cannot bring IPRs against public
universities to challenge their patents.
Notably, this immunity may be waived by the public university. Interestingly, UFRF brought an action in
state court for breach of a license agreement.
Covidien counterclaimed for a declaratory judgment of noninfringement and
then filed IPRs at the United States Patent and Trademark Office challenging
UFRF’s patents. Covidien then removed
the action to federal court; however, the federal district court sent the
action back to state court because of UFRF’s 11th Amendment immunity. That decision is pending resolution at the
U.S. Court of Appeals for the Federal Circuit (Federal Circuit).
Interestingly, the PTAB states:
Petitioner additionally argues that “immunizing patents owned
by alleged state entities from IPR proceedings would have harmful and
far-reaching consequences.” Opp. 15–17. Here, Petitioner’s arguments are
three-fold. One, invalid patents would stand simply because they are assigned
to a state entity. Two, a patent owned by a monetization foundation affiliated
with a state university would be insulated from the inter partes review
process. Three, determining whether an entity is entitled to sovereign immunity
is a fact-intensive inquiry that the Patent Office is not designed to
adjudicate.
With respect to the first two arguments, we are cognizant of
the fact that applying an Eleventh Amendment immunity to inter partes review,
absent waiver by the state entity4, precludes the institution of inter
partes review against a state entity entitled to Eleventh Amendment
immunity. This, indeed, is precisely the point of the Eleventh Amendment, which
is the preservation of the dignity afforded to sovereign states. “The
preeminent purpose of state sovereign immunity is to accord States the dignity
that is consistent with their status as sovereign entities.” FMC, 535
U.S. at 760 (citing In re Ayers, 123 U.S. 443, 505 (1887)). When
sovereign immunity conflicts with legislation, Congress may abrogate sovereign
immunity if it has unequivocally expressed its intent to abrogate the immunity
and has acted pursuant to a valid exercise of power. Seminole Tribe, 517
U.S. at 55. Petitioner does not point to, and we do not find there is, an
unequivocal, express intent by Congress in the AIA to abrogate immunity for the
purposes of inter partes review.
[Footnote 4 states: Because there is no related federal
district court patent infringement (or declaratory judgment of validity) case
brought by Patent Owner, we do not decide here whether the existence of such a
case would effect a waiver of sovereign immunity.]
Further, we are not persuaded that an application of
sovereign immunity to inter partes review will do violence to the patent
system. The Supreme Court in Florida Prepaid Postsecondary Education Expense
Board v. College Savings Bank, 527 U.S. 627 (1999) held that Congress does
not have authority to abrogate Eleventh Amendment immunity with respect to patent
infringement by the States, for “Congress identified no pattern of patent
infringement by the States, let alone a pattern of constitutional violations.” Id.
at 640. Based on the record before us, there is no evidence that the harm
to the patent system, described by the Petitioner, will come to pass, let alone
exists as a basis to divest States of sovereign immunity.
Finally, we are not persuaded that our tribunal cannot
perform the fact-finding duties that Petitioner alleges would be required to
determine whether an entity is entitled to sovereign immunity. Our rules and
procedures provide for discovery and motion practice which, at a minimum, would
provide the parties an opportunity to present arguments and supporting evidence
pertaining to sovereign immunity.
The Federal Circuit decision on this issue will be
interesting, particularly if public universities continue to bring more
litigation matters involving patents.
However, if there is a pending federal patent infringement claim brought by the university, I believe the PTAB (and Federal Circuit) will find a waiver of sovereign immunity. The monetization firm argument is interesting. [Hat tip to the Goodwin Keeping Tabs on the PTAB Alert for the lead to the case.]
No comments:
Post a Comment